A detailed history of Lynx1 Capital Management LP transactions in Merus N.V. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 1,793,866 shares of MRUS stock, worth $89.1 Million. This represents 32.08% of its overall portfolio holdings.

Number of Shares
1,793,866
Holding current value
$89.1 Million
% of portfolio
32.08%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$47.19 - $58.84 $84.7 Million - $106 Million
1,793,866 New
1,793,866 $89.6 Million
Q2 2024

Aug 14, 2024

BUY
$39.81 - $60.2 $48 Million - $72.6 Million
1,206,707 New
1,206,707 $71.4 Million
Q1 2024

May 15, 2024

BUY
$28.03 - $51.82 $10.5 Million - $19.4 Million
373,782 Added 32.93%
1,509,007 $68 Million
Q4 2023

Feb 14, 2024

SELL
$20.06 - $28.66 $300,900 - $429,900
-15,000 Reduced 1.3%
1,135,225 $31.2 Million
Q3 2023

Nov 14, 2023

SELL
$20.13 - $27.29 $46,299 - $62,767
-2,300 Reduced 0.2%
1,150,225 $27.1 Million
Q2 2023

Aug 14, 2023

BUY
$18.33 - $27.18 $1.55 Million - $2.3 Million
84,802 Added 7.94%
1,152,525 $30.3 Million
Q1 2023

May 15, 2023

BUY
$14.25 - $20.5 $3.04 Million - $4.37 Million
213,132 Added 24.94%
1,067,723 $19.6 Million
Q4 2022

Feb 14, 2023

BUY
$12.8 - $23.66 $3.09 Million - $5.71 Million
241,520 Added 39.4%
854,591 $13.2 Million
Q3 2022

Nov 14, 2022

SELL
$18.64 - $28.93 $7.24 Million - $11.2 Million
-388,146 Reduced 38.77%
613,071 $12.3 Million
Q2 2022

Aug 15, 2022

BUY
$13.98 - $29.25 $1.51 Million - $3.15 Million
107,690 Added 12.05%
1,001,217 $22.7 Million
Q1 2022

May 16, 2022

BUY
$23.58 - $30.91 $2.6 Million - $3.4 Million
110,129 Added 14.06%
893,527 $23.6 Million
Q4 2021

Feb 14, 2022

BUY
$20.0 - $32.29 $15.7 Million - $25.3 Million
783,398 New
783,398 $24.9 Million

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.28B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Lynx1 Capital Management LP Portfolio

Follow Lynx1 Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynx1 Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Lynx1 Capital Management LP with notifications on news.